Abstract
Interleukin 1 induced proteoglycan loss from cartilage in vitro was prevented by a biochemical inhibitor of metalloproteinase activity. The inhibitor also partially relieved the inhibition of proteoglycan synthesis caused by interleukin 1. The loss of glycosaminoglycan by rat and human femoral head cartilage in response to human recombinant interleukin 1, (rhIL-1p3) was established, and the modulation of this loss by the metailoproteinase inhibitor U27391 was investigated. Rat femoral head cartilage consistently lost glycosaminoglycan in response to rhIL-l1 whereas only a proportion (30%) of normal human femoral head cartilage did so. Concentrations of 10-100 tmol/l U27391 inhibited the action of rhIL-1l on rat femoral head cartilage, reversing both the loss of glycosaminoglycan and the inhibition of glycosaminoglycan synthesis. U27391 also prevented the reduction in glycosaminoglycan content ofthose human femoral head cartilage explants responsive to rhIL-13. Metalioproteinase inhibition therefore prevents rhIL-1 induced glycosaminoglycan loss by rat and human femoral head cartilage, suggesting that inhibitors of such enzymes may prove to be of therapeutic benefit in erosive diseases in humans.
(Ann Rheum Dis 1993; 52: 3743) Osteoarthritis (OA) and rheumatoid arthritis (RA) cause substantial articular cartilage erosion and loss of matrix in the affected joints of patients, which can lead to a severe compromise of function. Fundamental experiments by Fell and Jubb' identified the importance of synovium derived catabolic factor(s) which were capable of inducing cartilage damage in vitro, a constituent of which was later identified as interleukin 1 (IL-1).2 Interleukin 1 has since been implicated in the cartilage damage seen with OA and RA. It is synthesised by the diseased synovium in OA and RA3 4 and can be found in synovial fluids from patients with OA and RA. [4] [5] [6] [7] It is well established that recombinant human IL-1 (rhIL-l) can induce matrix loss, usually assessed as the loss of sulphated glycosaminoglycans, from the cartilage of several animal species in vitro2`1 and in vivo.12-14 Initial case reports using IL-1 harvested from cells illustrated that it was possible to induce degradation of human cartilage.'5 16 It was not until later, however, that rhIL-113 was shown unambiguously to degrade normal articular cartilage and then only after prolonged (14 days) incubation with specimens from certain subjects. 7 There is evidence that cartilage matrix degradation stimulated by IL-1 involves the action of metalloproteinases. For example, articular cartilage from pigs which is incubated with IL-1 releases proteoglycan fragments consistent with the action of one or more enzymes of this type.8 18 Although it can be shown that classical metalloproteinase inhibitors such as EDTA, 1, 10-phenanthroline, and a2 macroglobulin will reduce the activity of this class of IL-I inducible enzyme in isolation, 20 22 26 27 direct evidence that the inhibition of these enzymes in situ will prevent the destructive action of IL-1 is sparse, if only due to non-specific actions of the agents on the chondrocyte,28-30 or size exclusion from the cartilage. Several series of substrate inhibitors have been developed for an IL-1 inducible rabbit chondrocyte metalloproteinase, namely thiol, carboxyalkyl and hydroxamic acid peptides,9 31 with the aim of developing agents which will alleviate cartilage destruction in arthritic disease.32 Of these, the hydroxamic acid peptides are the most potent and two have been reported to inhibit IL-1 induced proteoglycan loss from rabbit articular cartilage in vitro.9 Chemicals of this series are effective against the rabbit chondrocyte metalloproteinases collagenase and proteoglycanase which are induced by IL-1.32 Here we describe experiments which assessed the ability of a hydroxamic acid peptide, U27391, to modulate IL-1 induced proteoglycan loss and synthesis inhibition by rat femoral head articular cartilage and compared this with the same tissue obtained from humans. Macroscopically normal slices ofhuman cartilage were obtained from the femoral heads ofpatients undergoing hemiarthroplasty following osteoporotic subcapital fracture of the femoral neck. Biopsy samples (3 x 3 mm) were taken from the human femoral head cartilage slices using a biopsy punch and each was cut in half. The two pieces were cultured and incubated as described in detail elsewhere. 7 In brief, one half (control biopsy) was cultured in 2 ml RPMI 1640 containing 2 mM L-glutamine, 100 U/ml penicillin and 100 ,ig/ml streptomycin, 25 mM HEPES and 5% normal human AB serum. The other half (treated biopsy) was cultured in 2 ml RPMI 1640 containing either 10 ng/ml rhIL-1l alone or 10 ng/ml rhIL-l, plus U27391 (1-100 ,tmol/l). Each treatment was tested on 10 biopsy samples.
The cultures were incubated for 14 days at 37°C in a humidified atmosphere of C02/air, and the media changed every two days. At the end of the culture period, the biopsy samples were blotted dry, weighed, and assayed for glycosaminoglycan using the technique described for rat femoral head cartilage. The glycosaminoglycan content of each half biopsy sample was expressed as micrograms glycosaminoglycan per milligram cartilage. The cartilage glycosaminoglycan content of each treated biopsy sample was compared with its paired untreated control using the Wilcoxon test. Owing to the zonal variation in the proteoglycan content of the human femoral head cartilage, the results were expressed as the percentage reduction in proteog]ycan content induced by rhIL-1f3, calculated as follows. % reduction in cartilage glycosaminoglycan= 100 -((glycosaminoglycan in treated biopsy/glycosaminoglycan in control biopsy) x100)
MATERIALS
Recombinant human IL-1lB produced by the expression of the carboxyl terminal 153 amino acids of the 269 amino acid precursor in Escherichia coli and purified to homogeneity as assessed by sodium dodecylsulphate polyacrylamide gel electrophoresis was obtained from Roussel UCLAF, Paris. Its activity in the lymphocyte activation factor assay was 100 pg per unit and the endotoxin content was less than 1 ng/mg as determined by the Limulus glucose, especially when compared with 2'0 g/l glucose DMEM. Spontaneous glycosaminoglycan loss into the medium was also considerably higher from the latter samples. Incubation in RPMI 1640 gave a comparable spontaneous loss of glycosaminoglycan to 4-5 g/l glucose DMEM, though slightly and statistically significantly lower. Incubation with 100 ng/ml rhIL-l, showed that stimulated glycosaminoglycan release was highest (a 123% increase; p<0 001) in the presence of 4-5 g/l glucose DMEM, whereas that in the presence of RPMI 1640 was less significant (33-7%; p<005 (1-6) ng/ml; n=6). There was no evidence of a preferential sensitivity of either glycosaminoglycan loss or 35 [S]sulphate uptake to the action of rhIL-1, (fig 2) at five days of incubation. As 100 ng/ml rhIL-1l3 gave the greatest effect, this concentration was used when assessing the actions of U27391. Recombinant human interleukin 113 at 10 ng/ml also stimulated human femoral head cartilage explants to lose glycosaminoglycan over 14 days. The reduction, compared with explants cultured with medium alone, was 18-6(2-6)% (n=10; p<0 005), 11-0(2-5)% (n=10; p<0 003), and 21-0(3-1)% (n=10; p<0 001) for cartilage from three subjects. In contrast, specimens from six other subjects showed no significant reduction in glycosaminoglycan content ranging from 1 to 8% loss (n=10). As 10 ng/ml rhIL-l,B gave an appreciable loss of glycosaminoglycan from human femoral head cartilage, this concentration was used when assessing the action of U27391.
MODULATION OF RAT FEMORAL HEAD CARTILAGE GLYCOSAMINOGLYCAN LOSS AND SYNTHESIS BY U27391
The action of U27391 on the basal unstimulated release of glycosaminoglycan into the incubation medium was investigated. Figure 3 U27391 in the presence of 10 ng/ml rhIL-1l and fig 5 shows that these explants lost significantly less glycosaminoglycan than those incubated with rhIL-1f, alone. The loss of glycosaminoglycan content from 10 biopsy samples was reduced from 18-6(2-6)% to 10-4(2-5) (p<0O01), 5-6(4-1) (p<0 01) and human cartilage explants is <10 [tg/ml, which is less than the limit of detection of the glycosaminoglycan assay. The most likely explanation for this finding is that as the glycosaminoglycan content of the explants averages about 150 ,ug (4 5 mg at 33 ,ug glycosaminoglycan/mg mass) and only 20% was lost, then at most only 30 ,ug will be released over the 14 day incubation period. As the medium was collected every two days, it would contain less than 5 ,ug/ml on average.
The main finding reported here is that rat femoral head cartilage responds to IL-1 with a dose dependent loss of proteoglycan into the incubation medium coupled with a reduction in [35S]sulphate uptake and thus proteoglycan synthesis. Likewise the human femoral head cartilage samples chosen for this study responded with a reduction in proteoglycan content. Rat femoral head cartilage in general appears to be less sensitive to rhIL-1, than human femoral head cartilage, probably as a result of the species difference, which necessitated the use of 100 ng/ml rhIL-113 as opposed to 10 ng/ml in human femoral head cartilage when assessing the effect of U27391. In the two instances, Although showing that the inhibition of cartilage degradation by reducing metalloproteinase activity in human cartilage is a promising approach to the problem of cartilage degradation in disease, the data presented here conversely illustrate the importance of metalloproteinases in rhIL-1j3 induced proteoglycan loss. U27391 is active against the proteoglycanase and collagenase released by IL-I stimulated chondrocytes, but is tenfold more active against the former (IC50 4-2x 10-8 and 41 x 10-7 mol/l respectively). 32 Other as yet uncharacterised mechanisms of cartilage degradation are being revealed, however. Studies of the proteoglycan fragments released from stimulated cartilage in vitro have identified the initial sites of cleavage to be between the GI and G2 globular domains of the proteoglycan core protein. 40 41 Interestingly, a major site of cleavage on the core protein uncharacteristic of that required by stromelysin has been identified. 42 The involvement of cysteinyl proteases has also been shown in the degradation of discs of bovine nasal septum with the use of the li'ophilic cysteinyl protease inhibitor EP475. 4 Other inhibitors without lipophilicity were found to be inactive, indicating either intracellular compartmentalisation of the enzymes or their release into other loci requiring membrane penetration. It is unknown if these mechanisms are important in the initial processes for the cleavage of the proteoglycan core protein as fragments characteristic of cysteinyl proteinase activity are not found. Despite these possibilities, metalloproteinase inhibition with U27391 remains effective, and could reflect the relatively uncharacterised nature of the enzymes against which it was developed.21 22 4 Although U27391 reduced rhIL-1, stimulated and unstimulated proteoglycan loss to less than basal levels to a similar degree, it remains to be shown at which position the remaining core proteins are cleaved to determine the residual mechanisms under these conditions.
In the absence of effective protection against cartilage erosion in RA and OA, it is promising to note that an agent developed as an inhibitor of rabbit metalloproteinase in in vitro animal systems is effective using human cartilage. We conclude that the inhibition ofmetalloproteinase activity is an effective method of reducing rhIL-1 induced proteoglycan loss from rat and, more importantly, human articular cartilage. There is an indication that this inhibition may also result in more efficient proteoglycan retention or synthesis by cartilage under conditions of synthesis inhibition and requires further investigation.
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